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ABSTRACT
Objective: To illustrate an unusual mechanism causing hypoglycaemia.
Material and methods: A 76-year-old man presented with episodes of agitation and confusion and was resuscitated with oral glucose gel 
when found to be hypoglycaemic.
Results: A CT scan for an abdominal mass con?rmed a solitary ?brous tumour (SFT). The sarcoma multidisciplinary team suggested 
conservative management. The patient’s episodic hypoglycaemia was managed with diet modi?cation including corn-based starch, 
scheduled snacks and dexamethasone. Glucose levels were within normal range at discharge from hospital. The patient was referred to the 
palliative care team for follow-up.
Conclusion: SFTs causing non-islet cell tumour hypoglycaemia are dif?cult to treat.
LEARNING POINTS
 To be aware of rarer causes of hypoglycaemia and to consider unusual causes in acute presentations of hypoglycaemia, especially in 
patients who do not have diabetes.
 This case illustrates the importance of a thorough general physical and systemic examination, as identifying the abdominal mass is 
essential to the early diagnosis of this rare condition.
• Solitary ?brous tumours causing non-islet cell tumour hypoglycaemia are dif?cult to treat, and even when surgical resections are 
applicable, recurrence rates are high.
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INTRODUCTION 
Spontaneous hypoglycaemia may be caused by insulin secreted from a functional tumour of the pancreatic islet cells, hypoadrenalism, 
hypopituitarism or liver pathology. Hypoinsulinaemic hypoglycaemia as a paraneoplastic syndrome (non-islet cell tumour hypoglycaemia, 
NICTH) is a rare complication of some tumours[1]. Excessive production of insulin-like growth factor-2 (IGF-2) by the tumour cells stimulates 
insulin receptors and increased glucose use. If this rare syndrome is not suspected, it may be life-threatening and may lead to cerebral 
hypoxia and death. We report the case of a patient with NICTH caused by a solitary ?brous tumour (SFT).
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Figure 1: CT scan showing the mass in abdomen.
CASE REPORT
A 76-year-old male ex-miner presented to the emergency assessment unit with agitation and confusion and a blood glucose level of 2.1 
mmol/l. There was a history of a weight loss of 5–8 kg within the previous 6 months.  His past medical history included hypertension, benign 
prostatic hypertrophy, left shoulder hemiarthroplasty, osteoarthritis and age-related macular degeneration. He had no signi?cant family 
history of illness. 
On examination he was afebrile and euvolaemic after the paramedics had resuscitated him with intravenous dextrose. There was an intra-
abdominal smooth, non-tender, non-ballotable right upper quadrant mass on examination.
During his hospital stay, the patient had multiple episodes of hypoglycaemia that were managed with intravenous dextrose, oral dextrose 
gel, dexamethasone, corn-based starch in additional to meals, and frequent scheduled snacks as suggested by the dieticians.
The CT scan and abdominal angiogram showed a heterogeneous mass measuring 26×15×18 cm and with calci?cation, in the right upper 
retroperitoneum between the liver and right kidney (Fig. 1). The lesion had a rich blood supply from the branches of the right renal artery and 
directly from the aorta superior to the right renal artery. There was possible inferior venacaval invasion. There was con@uent mediastinal 
lymphadenopathy of uncertain signi?cance. 
Histology of the core biopsy showed a monomorphic spindle cell tumour with stromal ropey collagen. The expression of CD34 and BCL2, 
and lack of other signi?cant markers (CD117, DOG1, AE1/AE3, EMA, S100, Melan A, desmin and CD31) con?rmed the diagnosis of SFT. 
There was no cellular atypia, >3 mitoses per 10 high-power ?elds (hpf) or necrosis to suggest a de?nitive diagnosis of a malignant SFT. 
SFTs are categorised as tumours with intermediate biological potential but where the biological behaviour of individual tumours is 
notoriously dif?cult to predict. Tumours <15 cm in diameter in patients <55 years of age and with <4 mitotic ?gures per 10 hpf have been 
shown to be associated with a high risk of both metastasis and death[2]. With the rich blood supply precluding tumour chemo-embolisation 
and surgical intervention, the sarcoma multidisciplinary team concluded that the general outcome in this patient was likely to be poor.  
Table 1 tabulates the laboratory results when the patient was euglycaemic. The low-normal proinsulin levels exclude the possibility of ectopic 
insulin secretion, insulinoma or exogenous insulin administration as the cause of hypoglycaemia. The raised IGF-2 levels con?rm that this 
patient had Doege-Potter syndrome[3].
Plasma proinsulin levels, cortisol, IGF-1 and IGF-2 levels were also investigated. 
The patient’s episodic hypoglycaemia was managed with diet modi?cation including corn-based starch, scheduled snacks and dexamethasone. 
He responded well to the treatment without further episodes of hypoglycaemia. The patient was stabilised on dexamethasone and 
discharged with a glucagon pen and counselling to be followed up by the palliative team.
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DISCUSSION
NICTH linked with excessive production of IGFs and Doege-Potter syndrome[3] was ?rst reported in a patient with a spindle cell tumour with 
hypoglycaemia of unknown aetiology. 
The pathogenesis of NICTH appears to be incompletely processed IGF-2 (‘big’ IGF). IGF-2 leads to increased skeletal muscle glucose use, 
suppression of glucagon, growth hormone release and inhibition of hepatic glucose release, with resulting persistent chronic hypoglycaemia. 
It also has higher af?nity for insulin receptors and lower af?nity for insulin binding proteins (IGF-BP)[4], mimicking the action of insulin. The 
IGF-2:IGF-1 ratio of 16 (normal=3:1) in our patient is pathognomonic of NICTH as the cause of hypoglycaemia[4].
The aims of treatment in patients with NICTH include maintaining euglycaemia and where possible, curative excision of the IGF-2 producing 
tumour (IGF-2oma). Simple measures such as administration of glucose tablets or liquid, fruit juice or intravenous glucose can be used in 
the acute setting. The usual medical management for spontaneous hypoglycaemia in instances of insulinomas (which includes diazoxide, 
octreotide and glucagon) has some limited use in NICTH, but steroids are the mainstay of treatment. Steroids decrease the amount of ‘big’ 
IGF-2 by converting pre-pro IGF into IGF-2. They also re-establish the normal IGF:IGF-BP ratio. Supra-physiological doses of recombinant 
growth hormone increase IGF-BP, preventing interaction with insulin receptors and ultimately decreasing the chances of hypoglycaemia[5].
De?nitive treatment depends on the nature of the tumour. If the tumour is resectable, surgery is often curative. The metabolic alterations 
caused by NICTH are reversible in many patients after complete surgical excision of ‘big’ IGF-2 producing tumours. A search of the 
literature from 2004 to 2014 revealed around 58 IGF-2oma case reports, 21 which were SFTs (both malignant and benign). Chemotherapy, 
embolisation or irradiation may also be considered with a variable success rate in controlling hypoglycaemia.
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